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Summary Oestrogen receptor (ER) expression in breast cancer is regarded as a phenotype that may change
during the natural history of the disease or during endocrine therapy. It has been suggested that in up to 70%
of tumours that show acquired resistance the mechanism may be changed in ER status from positive to
negative. This paper proposes an alternative hypothesis that ER expression is a stable phenotype in breast
cancer. The paper reviews the literature on ER expression during the natural history of breast cancer in
patients and also presents data on the effect of endocrine therapy on ER expression. If the alternative
hypothesis is true it has important implications for treatment from chemoprevention to acquired endocrine
resistance in advanced disease. Equally, if the hypothesis is true, attempts to develop laboratory models of
endocrine resistance where ER-positive tumours become ER negative need to be re-evaluated.
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The oestrogen receptor (ER) is a 65 kDa oestrogen-binding
protein expressed by 46-77% of breast cancers (Walt et al.,
1976; Knight et al., 1977; Maynard et al., 1978; Brooks et al.,
1980; Osborne et al., 1980; Croton et al., 1981; Howell et al.,
1984; Hawkins et al.,1987a; Williams et al., 1987; Clarke and
McGuire, 1988). It is a generally held view that ER expres-
sion is not a permanent phenotype in breast cancer cells
(Allegra et al., 1980; Moolgavakar et al., 1980; Encarnacion
et al., 1993; Morrow and Jordon, 1993; Nomura et al., 1985;
Jordan, 1994; Paik et al., 1994). One reason for this view is
the belief that patients with ER-positive primary breast
tumours often develop ER-negative metastases in regional
lymph nodes or distant sites. This has been interpreted to
show that ER negativity correlates with more aggressive
tumour biology and loss of cellular control. A second reason
is the strong correlation between ER and therapeutic res-
ponse to primary endocrine therapy (Samaan et al., 1981;
Howell et al., 1984; Williams et al., 1987), which formed the
basis for early hypotheses of endocrine sensitivity and resis-
tance. Up to 60% of ER-positive tumours respond to hor-
mone therapy (e.g. Tamoxifen), while for ER-negative
tumours the figure is around 10% (Allegra et al., 1980;
Samaan et al., 1981; Williams et al., 1987). Therapeutic
response to endocrine therapy is not permanent and even-
tually all such tumours progress. As ER negativity is strongly
associated with primary resistance to endocrine therapy it is
generally accepted that when responding tumours subse-
quently progress that in the majority of tumours this is due
to loss of ER expression by the tumour (Allegra et al., 1980;
Moolgavakar et al., 1980; Nomura et al., 1985; Encarnacion
et al., 1993; Morrow and Jordan, 1993; Jordan, 1994; Paik et
al., 1994). This paper proposes the alternative hypothesis that
ER is a stable phenotype in breast cancer cells.
The discovery of monoclonal antibodies (Kohler and Mils-
tein, 1975) subsequently led to specific antibodies being
raised to ER (Green and Jensen, 1982). H222 and H226
identify different epitopes on the ER, the hormone-binding
and the DNA-binding domain respectively. Neither antibody
blocks the natural ligand, oestradiol, binding to ER. H222
forms the basis for two commercially available ER assay kits
- an enzyme immunoassay (EIA) and an immunocyto-
chemistry assay (ICA). The ER-EIA measures the concentra-
tion of ER and, like the ligand binding assay (LBA), is
reported in fmol mg-' cytosol protein (Nicholson et al.,
1986). The ER-ICA allowed assessment of tumour tissue
sections (King and Green, 1984; Walker et al., 1988).
The ER-ICA test revealed that in tumours measured as ER
positive by ligand-binding assays or EIA not all the tumour
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cells expressed ER (McCarty et al., 1986; Walker et al.,
1988). This led to studies defining the number of ER-positive
cells that a tumour required to accurately predict therapeutic
response to endocrine therapy (Walker et al., 1988; Gaskell et
al., 1989; Nicholson et al., 1991; Robertson et al., 1992). The
finding of ER-positive and ER-negative cells in most tumours
appeared to strengthen the belief that endocrine-sensitive
ER-positive cells, with an inherently better prognosis, would
eventually change to ER negative cells, both as the disease
progressed from primary to metastatic disease and also from
endocrine sensitive to endocrine resistant.
This concept has major implications, particularly in the
area of acquired resistance to endocrine therapy when
tumours initially respond and subsequently progress. ER exp-
ression has been shown to correlate strongly with primary
sensitivity or insensitivity of tumours to endocrine therapy.
Previous hypotheses have tried to fit acquired resistance into
the same explanation as primary insensitivity, i.e. ER
negativity. The alternative hypothesis that ER is a stable
phenotype in breast cancer cells is more consistent with both
the clinical and laboratory data.
Sources of variability in ER measurements
Before ascribing reported changes in ER status to biological
changes in breast tumours the extent of other potential
influences on ER measurements should be considered. Im-
proper handling of specimens and warm ischaemic time
(Newsome et al., 1981) both affect ER measurements.
Tumour heterogeneity is another source of error in ER
measurements. Previous LBA studies of multiple biopsies of
the same primary tumour at the same time had shown discor-
dant results for ER status between 17% and 32% (Kiang and
Kennedy, 1977; Tilley et al., 1978; Silfversward et al., 1980;
Straus et al., 1982; Davis et al., 1984). This intra-tumour,
intersample receptor variation was not time dependent as the
multiple biopsies were taken from each tumour at the same
time. Among other factors reported to affect ER measure-
ments are tumour cellularity (Hawkins et al., 1977; Davis et
al., 1984) and tumour necrosis (Masters et al., 1978; Silfvers-
ward et al., 1980; Euseli et al., 1981).
Variation in ER assays is a major factor in the interpreta-
tion of ER results. The potential sources of laboratory
variability have been well reviewed by Thorpe (1987). Intra-
laboratory variation in a number of studies using LBA is
reported to range from 15% to 34% (Hawkins et al., 1975,
1987b; Taylor et al., 1982; Davis et al., 1984; Bojar, 1986;
Anderson et al., 1989). Inter-laboratory variation, which is
usually higher than intra-laboratory variation, is also a
significant factor, even where laboratories participate ine-4 Oestrogen receptors in breast cancer
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external quality control programmes. Even between large
series in which differences might be expected to be small and
in which one cut-off value of 5 fmol mg-' cytosol protein has
been used to define ER positivity, significantly different rates
of ER positivity, as low as 51% (Cooke et al., 1979) and as
high as 76% (Hawkins et al., 1987a), have been reported.
Even the newer monoclonal antibody-based EIA has high
CVs. Intra-assay and interassay CVs range from 3.4% to
14.3% (Jordan et al., 1986; Nicholson et al., 1986) and 3.7%
to 16.7% (Bojar, 1986; Jordan et al., 1986; Leclerq et al.,
1986; Nicholson et al., 1986) respectively. The inter-
laboratory CV for EIA was reported to range between 10%
and 19% (Bojar, 1986; Leclerq et al., 1986).
ER and the natural history of breast cancer
Many studies have reported no correlation between ER
status and axillary lymph node status (Maynard et al., 1978;
Hahnel et al., 1979; Mason et al., 1983; Williams et al., 1987;
Hawkins et al., 1987a). Nevertheless, it has been assumed
that ER-negative cells have more metastatic potential. As a
corollary, it has been believed that metastatic deposits from
ER-positive primary tumours may be ER negative, reflecting
the change to a more metastatic phenotype. This view is not
supported by review of the literature.
Hahnel and Twaddle (1985) reviewed 20 published studies
in the literature on ER status of synchronous primary and
secondary concurrent breast cancer. Of the 516 cases
reviewed, the average discordance rate was 18%. The study
also reported that changes between primary and metastases
could be either ER positive changing to negative or vice
versa. In addition, it was also noted that when both primary
and metastases provided ER positive tumours the concentra-
tion of ER could be higher or lower in metastases. Hahnel
and Twaddle (1985) also reviewed ER status in sequential
primary and secondary breast carcinoma paired biopsies in
405 cases. In 18 studies reviewed they found a 21% major
discordance rate. In these asynchronous tumours the concen-
tration of ER was higher in the primary tumour or the
metastasis in an equal number of cases. Other studies have
shown similar results (Bishop, 1982; Peetz et al., 1982; Har-
land et al., 1983).
Studies of ER in paired primary and metastatic tumours
have a discordance rate that can be explained by the sources
of variation in ER measurements discussed above. The most
striking findings are that the rate of discordance between the
primary tumour and metastases is particularly low and that
any changes in ER status between primary and metastases
can be either ER positive to ER negative or vice versa. These
findings argue strongly against phenotypic drift of ER
(positive to negative) during the natural history of the un-
treated disease.
That phenotypic drift does not occur between primary
invasive cancer and metastatic disease raises the issue of
whether ER expression changes from preinvasive to invasive
breast cancer. Studies of ER in ductal breast carcinoma in
situ (DCIS) have reported positivity in between 32% and
80% of tumours depending on the cut-off level chosen for
positivity (Giri et al., 1989; Malafa et al., 1990; Bur et al.,
1992; Pallis et al., 1992; Soomro et al., 1992; Poller et al.,
1993; Wilbur and Barrows, 1993; Murphy et al., submitted).
The positivity rates for DCIS are similar to reported rates for
invasive breast cancer, which argues against phenotypic drift
as tumours progress biologically from preinvasive to invasive
carcinoma. In the study that reported the highest rate of ER
positivity, 80% in 100 cases of DCIS, only 38 had pure in
situ cancer without associated invasive carcinoma (Bur et al.,
1992). In the group of pure in situ cancers the ER positivity
rate was 65% (25/38). In the group with associated invasive
carcinoma the ER positivity rate was (91%). This finding by
Bur et al. may be important as it suggests that invasion does
not correlate with ER-negative tumours, rather if anything
with ER-positive tumours. This challenges concepts of the
comparative invasive potential of ER-positive tumours. How-
ever, while there may be a statistical correlation between
ER-positive tumours and invasion we know that virtually all
ER-positive tumours contain a varying proportion of ER-
negative cells. The relative importance of ER-negative or
-positive cells or their interaction in tumour invasion requires
further investigation.
The expression of ER in normal breast tissue has also been
examined. Walker et al. (1992) reported that ER negativity
(<2% cells staining) was more common in the normal
breast tissue of premenopausal compared to post-menopausal
women. Normal ductal structures had a higher number of
ER-negative cells (>50% ER negative) in premenopausal
patients (88%) compared to post-menopausal (62%). The
paper suggested that these ER-negative cells may be a dor-
mant hormone-responsive cell population down-regulated by
circulating oestrogens. A cut-off level for ER positivity of
2% cells for ER may still underestimate the low level of ER
expression in normal tissue. In a recent publication Howell et
al. (1994) reviewed the literature and reported that in 94% of
normal breast tissue specimens one or more epithelial cells
was reported as ER positive.
In normal breast tissue ER-negative cells predominate over
ER-positive cells in terms of numbers. This is in contrast to
breast tumours in which 70% of tumours show expression of
ER in >5% of tumour cells. Premenopausal patients in
particular appear to maintain most normal breast epithelial
cells in an ER-negative phenotype as assessed by immuno-
cytochemistry. Walker et al. (1992) suggest that there is a
physiological control of cellular ER negativity and certainly
in premenopausal patients ER negativity increases during
weeks 2-3 of the cycle (Markopoulos et al., 1988; Walker et
al., 1992; Howell et al., 1994) just after the peak of serum
oestradiol has been reached. However, it is clear that the vast
majority of normal breast epithelial cells are phenotypically
ER negative. This too argues against phenotypic drift from
normal tissue through preinvasive to invasive and then
metastatic tumour tissue.
ER and Endocrine Therapy
Laboratory data
Most human breast cancer cell lines have been established
from ER-negative rather than ER-positive tumours, presum-
ably reflecting biological differences between such tumours
important in establishing in vitro cell lines. ER-negative cell
lines have not been reported to spontaneously change in
culture and express ER. The most common ER-positive cell
lines are MCF-7 and its numerous derivatives, T47D and
ZR-75 and its sublines. It is striking that with these cell lines
and in particular MCF-7, which is the most widely inves-
tigated breast cancer cell line, that there are no reports of
spontaneous change in ER phenotype when the cells are
being passaged in serum-free or fetal calf serum (FCS).
Moreover, even when selection for endocrine resistance in
MCF-7 cells has been successfully achieved it would appear
that in very few cases has this involved loss of ER (Van den
Berg et al., 1989; Murphy et al., 1990).
Other authors have reported loss of oestrogen sensitivity in
T47D and ZR-75 cell lines (Daly and Dabre, 1990) and in
T47D and LY2 (a derivative of MCF-7) cell lines (Mullick
and Chambon, 1990), without loss of ER. Furthermore, in
both T47D and LY2 structurally the ER was wild type
(Mullick and Chambon, 1990). Another group started with
ER-positive MCF-7 cells that were both oestrogen sensitive
and inhibited by the partial anti-oestrogen, tamoxifen, and
the specific anti-oestrogen, ICI 182,780; from this 'parental'
cell line various sublines have been established (Clarke et al.,
1994). MCF7/LCC1 was derived from a variant MCF-7
xenograft, MIII, which grows without E2 in nude mice but is
sensitive to the mouse's endogenous E2 in that ablation of
ovarian function results in the tumour xenografts regressing
(Yano et al., 1992). MCF7/LCC1, the ex vivo culture of
MIII, is insensitive to E2 in vitro culture but is sensitive to
tamoxifen and ICI 182,780. MCF7/LCC2 was derived fromLCC1 cultures grown in increasing concentrations of tamox-
ifen. It is therefore resistant to tamoxifen but not to ICI
182,780 (Clarke et al., 1994). MCF7/LCC9 was derived from
MCF-7 cells grown in the presence of ICI 182,780. It is
resistant to ICI 182,780 with cross-resistance to tamoxifen,
yet it remains sensitive to E2. These cell lines retain levels of
ER expression similar to the parental MCF-7 line, despite
successful selection for endocrine resistance (Brunner et al.,
1993a,b).
Two groups have reported in vivo experiments with MCF-7
xenograft tumours in which the tumour growth was initially
inhibited by tamoxifen but subsequently tamoxifen, which is
known to have oestrogenic properties, stimulated tumour
growth (Osborne et al., 1987; Gottardis and Jordan, 1988;
Osborne et al., 1991). The ER was normal in these
tamoxifen-resistant tumours (Osborne, 1993). Introduction of
the specific anti-oestrogen ICI 164,384 or ICI 182,780 at that
point inhibited the tamoxifen-stimulated growth (Gottardis et
al., 1989; Osborne et al., 1994). It would appear that in the in
vivo model too, resistance to tamoxifen does not involve loss
of a functioning ER, demonstrated by the subsequent inhibi-
tion of tumour growth by the pure anti-oestrogens.
Clinical data
ER and therapeutic response ER expression in primary
breast tumours correlates strongly with response to first-line
hormone therapy, the most commonly reported being the
anti-oestrogen, tamoxifen. Response rates of between 30%
and 65% have been reported in ER-positive tumours, wheth-
er by ligand binding assays (McGuire et al., 1975; Walt et al.,
1976; Roberts et al., 1978; Lippman and Allegra, 1980;
Osborne et al., 1980; Paridaens et al., 1980; Campbell et al.,
1981; Williams et al., 1987; Anderson et al., 1989; Robertson
et al., 1989) or the newer monoclonal antibody-dependent
EIA (Robertson et al., 1992) and the ICA (Jonat et al., 1986;
McClelland et al., 1986a,b; Coombes et al., 1987; Hawkins et
al., 1988; Robertson et al., 1992). Within the group of ER-
positive tumours the response rate increases as the tumour
ER concentration (McGuire et al., 1978; Lippman and
Allegra, 1980; Osborne et al., 1980; Campbell et al., 1981;
Williams et al., 1987; Anderson et al., 1989) or ER expres-
sion (Coombes et al., 1987; Gaskell et al., 1989) increases.
The response rate is also higher in tumours in which the ER
is functional, as assessed indirectly by the expression of
progesterone (PgR) (Brookes et al., 1980; Osborne et al.,
1980; Brenner et al., 1988).
The response rate for ER-negative tumours has varied for
LBA between 0% and 17% (Walt et al., 1976; Lippman and
Allegra, 1980; Osborne et al., 1980; Paridaens et al., 1980;
Williams et al., 1987; Anderson et al., 1989), for EIA 8%
(Robertson et al., 1992) and for ICA between 0% and 11%
(Jonat et al., 1986; McClelland et al., 1986a,b; Robertson et
al., 1992). As noted above PgR subdivides ER-positive
tumours. A more powerful factor for subdividing ER-
negative tumours is epidermal growth factor receptor
(EGFR) expression, which is inversely related to ER expres-
sion (Sainsbury et al., 1985; Toi et al., 1989; McClelland et
al., 1993). ER-negative tumours which do not express EGFR
are usually more responsive to primary endocrine therapy
(66% response rate) compared with ER-negative/EGFR-
positive tumours (5% response rate), although the degree of
expression of EGFR (i.e. percentage of cells EGFR positive)
did not affect the response rate or post-metastases survival
(McClelland et al., 1993).
In overtly ER-positive tumours ER and EGFR expression
is mutually exclusive on individual tumour cells (Sharma et
al., 1994). In overtly ER-positive tumours there exists a
population of tumour cells (approximately 25%) that are ER
negative/EGFR positive, a phenotype that in overtly ER-
negative tumours is a marker of endocrine unresponsiveness.
Lower objective response rates, increased static disease and
tumour progression rates are found as the percentage of
ER-negative cells (presumably also EGFR positive) increases
in overtly ER-positive tumours. It may be that the ER-
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negative/EGFR-positive subpopulation of cells simply does
not respond to endocrine manipulation, accounting for the
higher tumour progression rate and also the poorer quality
of response (static disease, partial remission) when it occurs
in such tumours. However, individually some such tumours
do undergo complete response and the precise cellular
mechanism that may include response in ER-negative/
EGFR-positive tumour cells is not clearly understood.
The ER-negative/EGFR-positive cell population in overtly
ER-positive tumours may be controlled indirectly through
paracrine-mediated effects from the hormone-sensitive ER-
positive/EGFR-negative tumour cells. ER-mediated pathways
can initiate transcription of growth factors (e.g. transforming
growth factor alpha) which interact with EGFR (Roberts et
al., 1983). Other studies have shown that endocrine therapy
can influence expression of both these receptors (Ewing et al.,
1989). The dual receptor phenotype may not be irreversibly
fixed. Alteration in the receptor expression may be an alter-
native explanation why overtly ER-positive tumours with
ER-negative/EGFR-positive cell subpopulations do some-
times respond completely to endocrine therapy. Sharma et al.
(1994) have suggested that the mutually exclusive staining for
ER or EGFR on individual tumour cells raises the possibility
that ER and EGFR expression have either a common
regulating mechanism or both pathways interact to regulate
the expression of the other receptor. Either of these poss-
ibilities may be relevant in controlling the growth of popula-
tions of ER-negative/EGFR-positive cells.
A number of factors are known to regulate the level of ER
expression in human breast tumours and cell lines without
involving permanent loss of ER. The potential interaction
between ER and EGFR expression in subpopulation of cells
does not negate the hypothesis that ER is a stable phenotype
in breast tumours. However, the effect of endocrine therapy
on the co-expression of these two receptors will be an inter-
esting observation and one that is currently being evaluated.
Effect of endocrine therapy on ER
Studies of ER expression in sequential tumour biopsies from
patients on tamoxifen have not reported consistent results.
Tamoxifen has been calculated to have a half-life of 5.3 days
(Wilkinson et al., 1980) and it is still measurable in patients'
blood 6 weeks after stopping tamoxifen therapy (Fabian et
al., 1981). In early studies virtually all the repeat tumour
biopsies were taken with the patients on tamoxifen treatment.
It was subsequently recognised that tamoxifen could compete
with the labelled oestradiol in the LBA giving a false ER-
negative result. Undoubtedly these early ligand binding
studies using LBAs (Namer et al., 1980; Waseda et al., 1981;
Taylor et al., 1982; Noguchi et al., 1988) contributed to the
concept of ER-positive cells becoming tamoxifen and anti-
oestrogen resistant by becoming ER-negative tumours and
are therefore difficult to interpret.
Monoclonal antibodies to ER made it possible to assess
ER status of tumours even when patients were on tamoxifen.
An early study reported that tumours biopsied after first-line
endocrine therapy were as likely to be ER positive as
tumours biopsied before first-line endocrine therapy (Coom-
bes et al., 1987). This study gave indications even at this
early stage that ER expression was a stable phenotype,
although this was not commented on by the authors. One of
the first studies to report on ER in sequential tumour biop-
sies using ICA reported on 23 tumours biopsied before and
during (1-4 months) tamoxifen therapy (Robertson et al.,
1991). There was no significant difference in the ER expres-
sion of the paired biopsies. Six tumours were negative on
both biopsies; two patients had static disease and four had
progressive disease. Seventeen were positive on initial biopsy:
14 of these were positive on repeated biopsy and three
negative. The clinical responses of these latter patients was
not published in the original report but have now been
reviewed. In the latter three patients one had a complete
response, one a partial response and the third progressiveOestrogen receptors in breast cancer
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disease. Only 1 of the 16 patients with tumours ER positive
on both biopsies had progressive disease after 6 months on
tamoxifen therapy. In this particular patient the repeat
biopsy was performed after 2 months on tamoxifen while the
patient's disease was static; progression of disease in this
patient was diagnosed after 6 months' tamoxifen treatment.
In none of these patients were repeat biopsies taken at the
time of disease progression. Another study reported no
change in ER but this was on short-term tamoxifen therapy
- median 21 days (range 6-65) (Clarke et al., 1993). A
further study examining the effect of short-term tamoxifen
therapy (<1 month) in 19 patients also reported no change
in ER expression (Murray et al., 1994). However, again few
if any tumours would be progressing at the time of the
second biopsy in the latter two studies. They therefore do not
answer whether there is a change between tumour ER status
pretreatment and at progression on tamoxifen.
One study reported tamoxifen concentrations in serum and
tumour tissue in patients with primary resistance (n = 16)
and acquired resistance (n = 17). The authors commented
that the percentage of tumours ER positive in these two
groups were 37% and 88% respectively (Johnston et al.,
1994). ER expression pretamoxifen was not reported,
although the high expression of ER in the acquired resistance
group supports the hypothesis that ER expression is stable.
In a recent study of ER expression tumour biopsies were
obtained from 37 patients pretreatment, after 6 weeks and
after 6 months on tamoxifen therapy. On each sample an
H-score was calculated = (percentage of cells staining with
intensity of staining 1 x 1) + (percentage of cells staining
with intensity score 2 x 2) + (percentage of cells staining with
intensity score 3 x 3). The range for H-score is 0-300. Three
patients showed an H-score of zero on initial measurements
and these remained unchanged on all sequential biopsies.
One patient showed an H-score of 10 initially but the two
subsequent measurements showed H-scores of zero. In three
of these four patients the tumour progressed within 6 months
and in the fourth stable disease was recorded for 1 month
before tamoxifen was discontinued. In the remaining 33
patients tumours that were ER positive before tamoxifen
remained positive on sequential biopsies: ER expression was
either down-regulated (though detectable) or unchanged in
all three categories of partial response, static disease or prog-
ressive disease (Table I). In 6 of the 33 patients who prog-
ressed and in whom tumour biopsies were taken at the time
of progression on tamoxifen, ER was still present by ICA.
It is difficult to be certain whether the change in the
percentage of ER-positive cells is as a result of marked
down-regulation of ER in previously positive cells or whether
the balance between ER positive and ER negative has
changed, for example because of apoptosis in ER-positive
cells. In some tumours there is a decreased expression of ER
on the biopsy after 6 weeks' tamoxifen and this is maintained
at 6 months. If the decreased expression of ER at 6 weeks
was as a result of individual cells changing from ER positive
to ER negative or even as a result of an uncontrolled pro-
gressive growth of ER-negative cells, one would not expect to
see such tumours going on to a partial response at 6 months
as many achieve. The clinical results suggest that the change
in ER expression is caused by a down-regulation mechanism.
These clinical findings that ER-positive tumours that
become tamoxifen resistant do not lose ER expression are in
keeping with the laboratory data described above and have
implications for our understanding of acquired resistance to
tamoxifen. While ER status predicts for sensitivity or insen-
sitivity to first-line endocrine therapy, it appears to play little
or no part in predicting or determining acquired resistance.
This implies that the mechanisms of primary endocrine insen-
sitivity and acquired (secondary) endocrine resistance are
different. The former appears to be mediated via the ER (or
lack of it), the latter not. The second point arising from the
data and consistent with the point above is that these
findings explain the clinical studies reporting that tamoxifen
resistance does not necessarily mean complete endocrine
resistance.
In a study of the synthetic progestogen, megace, 97
patients had tumours that initially responded or remained
static on tamoxifen and then subsequently progressed, of
whom 60 (62%) were reported to show a further period of
response or static disease on second-line endocrine therapy,
megace. In contrast, of 66 patients whose tumours progressed
de novo on tamoxifen, only 17% showed an objective res-
ponse or static disease on megace (Robertson et al., 1989).
Response to megace was better predicted by response to
first-line tamoxifen than by tumour ER status. Similar res-
ponse rates following tamoxifen therapy have been reported
for second-line aromatase inhibitor therapy in post-
menopausal patients (Smith et al., 1981; Buzdar et al., 1982;
Harvey et al., 1982; Kaye et al., 1982; Murray and Pitt, 1982)
and for oopherectomy in premenopausal patients (Margreiter
and Wiegele, 1984; Sawka et al., 1986).
Two clinical studies have been reported using the specific
anti-oestrogen ICI 182,780. In the first study patients with
primary operable (Stage I/II) breast cancer were treated with
ICI 182,780 for 7 days between diagnosis and definitive
surgery (DeFriend et al., 1994). Patients were randomised to
receive no treatment (n = 19), 6 mg of ICI 182,780 daily
(n = 21) or 18 mg of ICI 182,780 daily (n = 16). Tumour
specimens were available before randomisation to either no
treatment or to ICI 182,780 and from the resected tumour at
definitive surgery. There was down-regulation of ER on ICI
182,780 both at the 6 mg and the 18 mg dose. At the higher
dose of ICI 182,780 (18 mg day-') five out of ten tumours
showed absence of ER expression immunocytochemically in
the primary tumour after 7 days' treatment (Nicholson et al.,
1994). The majority of ICI 182,780-treated tumours therefore
continued to express ER, although at reduced levels. In the
five tumours that did not express ER, it is much more likely
that after such short-term treatment the absence of ER exp-
ression is as a result of down-regulation rather than true loss
of ER. Down-regulation of ER can be induced in vitro by
short-term treatment of ER-positive MCF-7 cells by pure
anti-oestrogens (Nicholson et al., 1994) without actual long-
term loss of ER as already noted (Brunner et al., 1993a,b;
Clarke et al., 1994). Similarly, down-regulation was also
noted for oestrogen-inducible gene products PgR and pS2.
These findings are qualitatively similar to those reported with
tamoxifen except that reported down-regulation on tamox-
ifen was after 6 weeks. Nicholson reported that the fall in ER
expression after 7 days on 18 mg of ICI 182,780 was greater
Table I Changes during tamoxifen therapy of ER expression in 33 tumours ER positive on
pretreatment biopsy (repeat biopsy on tamoxifen vs pretreatment)
Time (months) from pretreatment to repeat biopsy
<6 months 6 months
UICC assessment at 6/12 PR SD PD PR SD PD
3 4 1 13 7 5
Change in ER Expression
Down-regulated (but present) 3 3 - 9 5 3
No change - 1 1 4 2 2
Up-regulated - - - - - -
PR, partial response; SD, static disease; PD, progressive disease.Oestrogen receptors in breast cancer
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than after tamoxifen therapy. The tamoxifen-treated tumours
were essentially the same group of tumours reported by
Clarke et al. (1993) when the median duration of tamoxifen
was 21 days - there was no significant down-regulation of
ER by that time. One explanation for the reported differences
between tamoxifen and ICI 182,780 could be the markedly
different affinity of the two compounds for ER. It may
therefore take longer for tamoxifen, which binds less avidly
to the ER, to induce down-regulation.
The second study with ICI 182,780 was a phase II study to
assess therapeutic efficacy (Howell et al., 1995). Patients who
had previously received tamoxifen as adjuvant therapy or as
initial therapy for advanced disease and deemed to have been
tamoxifen responsive were entered into the study. A total of
13/19 (69%) showed objective response or static disease on
ICI 182,780, 12/19 (63%) for more than 6 months' duration.
These second-line response rates are in keeping with those
referenced above for second-line megace or aminoglute-
thamide in post-menopausal patients or ovarian ablation as
second-line in premenopausal patients. With the median
duration of response not yet having been reached at 18
months (Howell et al., 1995) early indications are that ICI
182,780 may produce a longer duration of response than
megace or aminoglutethamide, with the possibility of a fur-
ther response if megace or aminoglutethamide is subse-
quently introduced. However, this will require confirmation.
As detailed above there appears to be continued expression
of ER during tamoxifen therapy in almost all ER-positive
tumours, even at the time of tumour progression. ICI
182,780 is known to bind to ER and the phase II study
results imply that in the 69% of patients whose tumours
responded the ER mechanism is still functional. Two patients
with locoregional recurrence had primary tumour tissue from
the time of their original diagnosis and a biopsy of the
recurrent tumour while in partial remission on ICI 182,780.
In the tumours of both patients there was continuing ER
expression after 20 months on ICI 182,780. In one patient
100% of tumour cells stained positive for ER in both the
primary tumour and the local recurrence (H-scores 180 and
160 respectively). In both tumour biopsies 100% of tumour
cells also expressed PgR. In the second patient 70% of
tumour cells in the primary tumour stained positive for ER,
while in the regional lymph node recurrence 65% of cells
stained positive on ICI 182,780 (H-scores 80 and 85 respec-
tively). PgR expression was only available on the primary
tumour - 95% of tumour cells expressed PgR (H-score 185)
(JFR Robertson, unpublished data).
Therefore whatever the mechanism of acquired resistance
to tamoxifen it does not, in the majority of cases, involve loss
of ER expression, or apparently of receptor functionality.
Possible mechanisms of acquired tamoxifen resistance such as
ER variants (Fuqua et al., 1991) are not the subject of this
paper. Neither is the question whether the tumours in the
remaining 30% of patients who were tamoxifen sensitive but
did not respond to second-line endocrine agents (e.g. ICI
182,780), still have a functioning ER. This would depend on
possible differences in the mechanism of resistance between
this 30% of tumours and the 70% that responded to both
tamoxifen and ICI 182,780. Tumours that responded to ICI
182,780 and subsequently progressed indicate that resistance
is also acquired to the specific anti-oestrogen. In the in vivo
experiments most tumour xenografts eventually developed
resistance to tamoxifen and to ICI 182,780. The clinical
findings are in keeping with xenograft experiments, which
also showed a functioning ER in the presence of acquired
endocrine resistance. If other mechanisms are responsible for
acquired resistance to tamoxifen this would explain why ER
is still expressed, still functional and yet is not as good a
predictor of response to second-line endocrine therapy com-
pared with prior response to tamoxifen.
The hypothesis of this paper is that ER expression is stable
in breast cancer cells. While expression of ER in tumour cells
is stable the relative or absolute number of ER-positive or
ER-negative cells may vary during the course of patients'
disease depending on a variety of host-tumour interactions.
However, the evidence which has accumulated suggests that
any relative or absolute change in the number of ER-positive
and ER-negative cells in a tumour is not as a result of
individual ER-positive tumour cells losing ER. If the
hypothesis is true there are important implications for treat-
ment from chemoprevention to acquired endocrine resistance
in advanced disease. Equally if the hypothesis is true
attempts to develop laboratory models of endocrine resis-
tance where ER-positive tumours become ER negative need
to be re-evaluated.
The concept that in breast cancers ER positivity drifts to
ER negativity as a natural process of selection and increasing
malignancy can no longer be supported. An alternative
hypothesis is that ER is a stable phenotype in human breast
cancer and ER positive-cells do not lose anti-oestrogen sen-
sitivity by becoming ER negative.
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